Temporal trends in vascular medication use in 8079 patients with systemic sclerosis: insights to inform future trials and therapeutic strategies from the EUSTAR cohort

作者：Stefano Di Donato, John David Pauling, Sheila Ramjug, Yannick Allanore, Edward Bernard Jude, Marie‐Elise Truchetet, Paolo Airò, L. P. Ananyeva, Andra Rodica Balanescu, Gonçalo Boleto, Francesco Paolo Cantatore, Patricia E. Carreira, Carolina de Souza Müller, Masataka Kuwana, Gianluca Moroncini, Marco Di Battista, Luc Mouthon, Madelon C Vonk, Elisabetta Zanatta, Marco Matucci‐Cerinic, Francesco Del Galdo, Michael J. Hughes, EUSTAR Collaborators, Serena Guiducci, Silvia Bellando-Randone, Ulrich Andreas Walker, Florenzo Iannone, Oliver Distler, Radim Bečvář, Otylia Kowal Bielecka, Maurizio Cutolo, Vasiliki Liakouli, Elise Siegert, Simona Rednic, Jérôme Avouac, Carlomaurizio Montecucco, László Czirják, Michele Iudici, Katja Perdan Pirkmajer, Bernard Coleiro, Dominique Farge Bancel, Kristofer Andréasson, Mislav Radić, Alexandra Balbir‐Gurman, Nicolas Hunzelmann, Luca Idolazzi, Christopher Denton, Jörg Henes, Vera Ortiz-Santamaria, Johannes Pflugfelder, Dorota Krasowska, Ivan Foeldvari, José António Pereira da Silva, Bojana Stamenkovic, Maria De Santis, Lidia P Ananieva, Philipp Klemm, Ulf Müller-Ladner, Klaus Søndergaard, Simone Negrini, Gabriella Szűcs, Anna-Maria Hoffmann-Vold, David Launay, Valeria Riccieri, Ana Maria Gheorghiu, Christina Bergmann, Francesca Ingegnoli, Vanessa M. Smith, Mette Mogensen, Maria Rosa Pozzi, Felix Lauffer, Marie Vanthuyne, Juan Jose Alegre-Sancho, Martin Aringer, Ellen De Langhe, Branimir Ani, Sule Yavuz, Svetlana Agachi, Alberto Cauli, Kamal Solanki, Esthela Loyo, Edoardo Rosato, Figen Yargucu Zhini, Rosario Foti, Britta Maurer, Marzena Olesinska, Jorge Juan González Martín, Emmanuel Chatelus, Ira Litinsky, Lesley Ann Saketkoo, Eduardo Mario Kerzberg, Breno Valdetaro Bianchi, Ivan Castellví, Massimiliano Limonta, Maura Couto, Camillo Ribi, Antonella Marcoccia, Thierry Martin, Lorinda S Chung, Tim Schmeiser, Dominik Majewski, Anna Wojteczek, Vera Bernardino, Gabriela Riemekasten, Yair M. Levy, Elena Rezus, Rossella Talotta, Sara Bongiovanni, Marek Brzosko, Hadi Poormoghim, Ina Kötter, Giovanna Cuomo, Oscar Massimiliano Epis, Petros Sfikakis, Daniel E. Furst, Ana-Maria Ramazan, Jeska de Vries‐Bouwstra, Alain Lescoat, Julia Spierings, Fabiola Atzeni, Masataka Kuwana, Arsene Mekinian, Mickaël Martin, Yoshiya Tanaka, Carmen-Pilar Simeón-Aznar, Philipp Klemm, Ulf Müller-Ladner, Magda Pârvu, Nicoletta Del Papa, Kastriot Kastrati, Jennifer Ben Shimol, Enrico Selvi, T. Soukup, Yasushi Kawaguchi, Andre Nuñez Conde, Marija Geroldinger‐Simić, Ignasi Rodríguez-Pintó, Percival D Sampaio-Barros, Ulrich Gerth, Marta Dzhus, Duygu Temiz Karadag, Anastas Batalov, Knarik Ginosyan, Vahan Mukuchyan, Valentina Vardanyan, Armine Haroyan, Len Harty, Mariela Geneva-Popova, Mohammad Ebrahim Naffaa, Cristina Maglio, Masato Okada, Iwata Futoshi · 发表于：Lara D. Veeken · 年份：2025 · DOI：10.1093/rheumatology/keaf290 · 被引用次数：9 · 研究领域：Systemic Sclerosis and Related Diseases、Pulmonary Hypertension Research and Treatments、Diagnosis and Treatment of Venous Diseases

OBJECTIVES: Systemic sclerosis (SSc) is characterized by widespread vascular damage resulting in digital and systemic vasculopathic sequelae. Although there are effective treatments available, vascular disease remains a significant cause of morbidity and mortality in SSc. Our aim was to describe patterns of vascular medication use in SSc, including examination for potential changes over time. METHODS: A cross-sectional study of SSc patients enrolled in the EUSTAR database meeting 2013 ACR/EULAR SSc criteria. Patients were divided into two time periods: 2012-2017 and 2018-2022. We analysed the prescription patterns of endothelin receptor antagonists (ERA), phosphodiesterase type-5 inhibitors (PDE5i), calcium channel blockers (CCB), intravenous iloprost, and antiplatelet therapies. Logistic regression was used to evaluate temporal trends and interaction effects. RESULTS: A total of 8079 patients were included. Significant increases over time were observed in the use of ERA (7% to 12%, P < 0.001), PDE5i (5.4% to 7.2%, P = 0.064), CCB (20% to 32%, P < 0.001) and anti-platelet therapies (15% to 20%, P < 0.001). There was a notable decrease in iloprost use (3.1% to 0.3%, P < 0.001). The prevalence of active digital ulcers (DU) decreased (16% to 13%, P = 0.040), while a history of DU (24% to 30%, P < 0.001) increased. Year-by-year and non-linear increases were noted for ERA and CCB whereas non-linear increase was observed for PDE5i. Year-by-year and non-linear decrease was observed ...